Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structure-activity relationship studies of 4-benzyl-1H-pyrazol-3-yl β-d-glucopyranoside derivatives as potent and selective sodium glucose co-transporter 1 (SGLT1) inhibitors with therapeutic activity on postprandial hyperglycemia.
Fushimi N, Fujikura H, Shiohara H, Teranishi H, Shimizu K, Yonekubo S, Ohno K, Miyagi T, Itoh F, Shibazaki T, Tomae M, Ishikawa-Takemura Y, Nakabayashi T, Kamada N, Ozawa T, Kobayashi S, Isaji M. Fushimi N, et al. Among authors: isaji m. Bioorg Med Chem. 2012 Nov 15;20(22):6598-612. doi: 10.1016/j.bmc.2012.09.037. Epub 2012 Sep 24. Bioorg Med Chem. 2012. PMID: 23062824
A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives.
Hirabayashi A, Mukaiyama H, Kobayashi H, Shiohara H, Nakayama S, Ozawa M, Miyazawa K, Misawa K, Ohnota H, Isaji M. Hirabayashi A, et al. Among authors: isaji m. Bioorg Med Chem. 2008 Aug 1;16(15):7347-57. doi: 10.1016/j.bmc.2008.06.017. Epub 2008 Jun 14. Bioorg Med Chem. 2008. PMID: 18585046
Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1).
Fushimi N, Teranishi H, Shimizu K, Yonekubo S, Ohno K, Miyagi T, Itoh F, Shibazaki T, Tomae M, Ishikawa-Takemura Y, Nakabayashi T, Kamada N, Yamauchi Y, Kobayashi S, Isaji M. Fushimi N, et al. Among authors: isaji m. Bioorg Med Chem. 2013 Feb 1;21(3):748-65. doi: 10.1016/j.bmc.2012.11.041. Epub 2012 Dec 5. Bioorg Med Chem. 2013. PMID: 23273606
Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor.
Shimizu K, Fujikura H, Fushimi N, Nishimura T, Tatani K, Katsuno K, Fujimori Y, Watanabe S, Hiratochi M, Nakabayashi T, Kamada N, Arakawa K, Hikawa H, Azumaya I, Isaji M. Shimizu K, et al. Among authors: isaji m. Bioorg Med Chem. 2021 Mar 15;34:116033. doi: 10.1016/j.bmc.2021.116033. Epub 2021 Jan 22. Bioorg Med Chem. 2021. PMID: 33581390
106 results